

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **1999-03-26** | Period of Report: **1999-03-24**
SEC Accession No. [0001032210-99-000384](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

PROCYTE CORP /WA/

CIK: **856072** | IRS No.: **911307460** | State of Incorpor.: **WA** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: **000-18044** | Film No.: **99573285**
SIC: **2834** Pharmaceutical preparations

Mailing Address

*154TH AVENUE N E
BLDG A 8511
REDMOND WA 98034-6900*

Business Address

*154TH AVE N E BLDG A 8511
REDMOND WA 98034
2068204548*

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

March 24, 1999

Date of Report
(Date of earliest event reported)

PROCYTE CORPORATION

(Exact Name of Registrant as Specified in Charter)

<TABLE>

<S>	<C>	<C>
Washington	0-18044	91-1307460
(State or Other Jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)

Building A, 8511-154th Avenue N.E., Redmond, WA 98052
(Address of principal executive offices, including zip code)

(425) 869-1239
(Registrant's telephone number, including area code)

</TABLE>

Item 5. Other Events

On March 24, 1999, NASDAQ announced that it would delist ProCyte Corporation's common stock from the NASDAQ National Market System.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

(c) Exhibits

99.1 Press release dated March 25, 1999 regarding the delisting.

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PROCYTE CORPORATION
(REGISTRANT)

Date: March 25, 1999

By: /s/ John F. Clifford

John F. Clifford, President and CEO

Date: March 25, 1999

By: /s/ Jerry Scott

Jerry Scott, Vice President and CFO

EXHIBIT INDEX

<TABLE>
<CAPTION>

Exhibit Number	Title
-----	-----
<S>	<C>
99.1	Press release dated March 25, 1999 announcing the delisting.

</TABLE>

FOR IMMEDIATE RELEASE
March 25, 1999
8:30 a.m. EST

ProCyte Contact
Jack Clifford,
President/CEO
(425) 869-1239
www.procyte.com

PROCYTE ON OTC BULLETIN BOARD

ProCyte Stock will Be Traded on OTC Bulletin Board

(Redmond, WA) - PR Newswire - ProCyte Corporation (PCY) today announced that the Nasdaq Listing Qualifications Panel has ruled that based on the continued trading of the Company's stock below \$1.00 per share that the stock will no longer be traded on the Nasdaq National Market.

Effective on March 25th, 1999, ProCyte stock will be traded on the OTC Bulletin Board.

ProCyte Corporation is a healthcare company that develops, manufactures and markets products for wound care, skin health and hair care. The Company's products incorporate its patented copper peptide technology and are marketed both directly and through distribution partners.